PM08-B takes Omega assets after no topping bid
Omega launched its sale process with Pioneering Medicines 08-B, Inc. as stalking horse for substantially all assets. The initial bid floor was a credit bid of not less than $11.461 million, plus assumed liabilities and cure costs, with expense reimbursement capped at $300,000 and no break-up fee. The motion set an April 1 bid deadline and April 3 auction date, underscoring that the case was structured around a rapid lender-backed 363 process from the outset source filing source filing.
No competing bids emerged, the stalking horse was selected as successful bidder, and the court approved the sale with section 363(m) good-faith findings. The later plan filing states the sale closed on April 25, 2025 and that the DIP facility was satisfied in full at closing, leaving the estate to proceed as a wind-down rather than continue an operating reorganization. For practitioners following value leakage and insider-deal dynamics, the important point is that the auction never materialized and Flagship-affiliated PM08-B ended up owning the assets on the stalking-horse path source filing source filing.